Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
Oct 19, 2026
MIAMI - Oct. 19, 2026 - PRLog -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP announced a significant manufacturing milestone today reporting completion of process validation for three commercial lots of its preservative-free intravenous ketamine ahead of the November 10, 2026, U.S. Food and Drug Administration (FDA) review goal date. The company also announced two-year room-temperature stability data showing no deterioration in purity, potency, or sterility without the need for preservatives. According to NRx, the stability results are consistent with the potential for a labeled shelf life of three years or longer. With commercially releasable drug supply now on hand pending approval of its Abbreviated New Drug Application (ANDA), NRx is advancing an important part of its preparation to serve American hospitals and clinics. The latest announcement adds substantial manufacturing progress to a growing corporate story that includes investigational depression treatments, robotic brain stimulation research, and an approximately $11.18 million government-funded clinical research contract.
NRXP's announcement is particularly important because process validation is a key manufacturing requirement under FDA Good Manufacturing Practices. The company reports that three commercial lots have been successfully manufactured under commercial conditions, marking completion of the process validation step described in its announcement. NRx thanked its manufacturing partner, Nephron Pharmaceuticals, based in West Columbia, South Carolina, for helping achieve this milestone and supporting domestic production of sterile injectable medicines. The company's focus on American manufacturing could be relevant to hospitals and healthcare providers seeking dependable access to essential medicines. NRx has identified preservative-free ketamine as a potential contributor to the drug-shortage market, although commercial distribution remains contingent on the necessary FDA approval.
The new stability information adds another important dimension. NRx reports that its completed two-year, real-time room-temperature stability analysis showed no deterioration in the product's purity, potency, or sterility without toxic preservatives. The company believes these results may support a labeled shelf life of three years or longer, subject to the applicable regulatory requirements. A longer potential shelf life could be valuable for healthcare facilities managing medication inventories, but the final labeled shelf life will depend on the approved product labeling. Together, process validation, stability data, and available commercial supply represent meaningful preparation for a potential launch.
The immediate regulatory milestone remains November 10, 2026, the announced Generic Drug User Fee Amendments (GDUFA) goal date for NRx's preservative-free ketamine ANDA. On October 15, the company reported receiving an FDA Discipline Review Letter requesting minor labeling changes and sample labeling incorporating the proposed proprietary product name, which remains under review. NRx stated that the requested changes were minor. The latest manufacturing announcement adds to this progress by reporting completion of the three process validation lots and the availability of commercial supply pending approval. The distinction remains important: manufacturing readiness is not the same as regulatory approval, and the FDA's final decision has not been announced in the supplied release. Investors will be watching for official updates as the goal date approaches.
Beyond its near-term ketamine opportunity, NRx continues to develop a broader portfolio focused on serious central nervous system conditions, including depression, post-traumatic stress disorder, and related disorders. Its NRX-100 program is preservative-free intravenous ketamine. The company has reported Fast Track Designation for development involving suicidal ideation in depression, including bipolar depression, and has pursued a separate New Drug Application pathway for that potential use. The ANDA and NDA are distinct regulatory pathways with different requirements, and progress in one should not be interpreted as approval under the other.
NRX-101, an investigational oral combination of D-cycloserine and lurasidone, represents another part of the company's development strategy. NRx has reported Breakthrough Therapy Designation for NRX-101 in suicidal bipolar depression. The company's interest in combining pharmaceutical approaches with advanced treatment technologies also underpins its SPARC-TMS initiative, announced September 30, 2026.
Under an approximately $11.18 million prime contract awarded by the Defense Advanced Research Projects Agency (DARPA), NRx Defense Systems is advancing research evaluating robotic, neuronavigated transcranial magnetic stimulation (TMS) combined with NRX-101 for treatment-resistant depression. The program is designed to investigate a single-day treatment protocol and brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America. The contract has an 18-month performance period, with approximately $6.7 million initially obligated and additional funding subject to appropriations and contract options. Clinical outcomes will be necessary to establish whether the approach can support further development.
NRx's HOPE Therapeutics subsidiary is also preparing to deploy advanced robotic TMS navigation technology at its Florida clinics. The company announced this initiative in September, connecting its clinical services platform with its broader interest in technology-enabled psychiatric care. These activities provide additional developments for investors to follow alongside the immediate manufacturing and regulatory milestones.
Financial resources and execution will remain important as NRx moves toward potential commercialization. In its August 17, 2026, second-quarter update, the company reported approximately $26.7 million in cash and cash equivalents as of June 30 and approximately $22.3 million in gross proceeds from an underwritten public offering. These are historical figures, not a statement of the company's current cash balance. Future funding requirements, manufacturing costs, commercial execution, and the timing of any approval will remain important considerations.
For investors following $NRXP, this announcement brings several concrete developments into focus: completion of three commercial process validation lots, two-year room-temperature stability data, and commercially releasable supply awaiting ANDA approval. Combined with the November 10 FDA goal date, the NRX-101 research program, and the DARPA-funded SPARC-TMS initiative, these developments give the company multiple milestones to monitor. The next stage will depend on the FDA's decision, the final approved labeling, and NRx's ability to translate its manufacturing preparation and research activities into measurable commercial and clinical progress. The company's progress offers an encouraging development story, while the ultimate outcome will depend on regulatory decisions, clinical evidence, financing, and execution.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: [email protected]
Phone: (917) 653-5122
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP | More news from this source
Press release distribution by PRLog
More News
China’s Liaoning carrier and USS Theodore Roosevelt may be in Philippine Sea at same time
China’s Liaoning aircraft carrier strike group sailed beyond the first island chain last week to reach the southernmost waters of the Philippines, suggesting an intent to position itself closer to ongoing US-Japan joint exercises. Philippine news channel BNC reported that the carrier group reached about 25 nautical miles (46km) east-southeast of Balut Island, the southernmost point of the Philippines, before sailing northeast on Friday. That positioned the warships past the first island chain, a...
‘Really terrified’: how a blood test could spare cancer patients an agonising wait
In the second of a four-part Health Matters wellness series on frontier medicine in Hong Kong, Fiona Sun looks into how a new PCR system can detect cancer, infections and birth defects within hours, and what it will take to bring such laboratory breakthroughs to patients. Part one can be found here. It began with a pimple-like lump on Audrey Kwan’s neck. Within a month, it had swollen to the size of a table tennis ball. But it took blood tests, a biopsy and CAT scans before the Hongkonger, then...
Hong Kong seeks bigger role for yuan in regional trade, treasury chief says
Hong Kong officials held discussions with finance ministers and representatives from economies such as Brunei during last week’s Apec meeting on reducing reliance on the US dollar and expanding the use of local currencies and the yuan for bilateral trade settlement, the city’s treasury chief has said. Secretary for Financial Services and the Treasury Christopher Hui Ching-yu on Sunday also shared lighthearted but telling anecdotes about the intangible gains made by the city from hosting the...
Perth beach closed after whale remains discovered
A popular Perth beach has been closed after a whale carcass was found on the sand, prompting a shark alert.
Doctor charged with manslaughter back at work
A doctor charged with manslaughter has been freed on bail and is back working at a major WA hospital.
Search for missing Perth man ramps up
Residents across Perth have been asked to check their backyards, sheds and security cameras as the search for a missing 24-year-old intensifies.
Four people shot in Queensland drive-by shooting
Four people have been shot in a drive-by shooting in Logan, with a woman left in a critical condition.
5-hour battle to bring hill fire near residential area in Tuen Mun under control
Hong Kong firefighters battled for five hours to bring a hill fire near a residential area in Tuen Mun under control on Sunday, with a government helicopter sent to help bring the flames under control. No injuries were reported, but the flames spread along the hillside near Shan King Estate, not far from two secondary schools, sending thick clouds of smoke billowing into the air. The blaze, reported at about 1.30pm, broke out in a patch of grass measuring about 10 metres by 20 metres (33 feet by...
How China’s regional leadership changes offer clues to the future of the Communist Party
China’s five-year leadership cycle is getting under way at a provincial level, with new teams being installed in a process that offers important clues to the future of the Communist Party at a national level. Last week, four provinces – Anhui, Henan, Shanxi and Xinjiang – wrapped up their respective party congresses and appointed new standing committees for the next five years. The meetings were held a week before a key party gathering in Beijing – known as the fifth plenum – that runs from...
Job training, housing, students' basic needs: L.A. community college candidates promise fixes
L.A. Community College District trustee candidates vie for three open seats, promising to tackle student housing, job training, and basic needs across campuses.
More storms a-brewin': L.A. could see its first rainy Halloween in over a decade
A shift in weather at the end of the week will bring a high chance of rain to deliver possibly the first rainy Halloween in Los Angeles since 2014.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.